CN Patent

CN109689663B — Menin-mll相互作用的螺二环抑制剂

Assigned to Janssen Pharmaceutica NV · Expires 2023-04-14 · 3y expired

What this patent protects

本发明涉及用于在哺乳动物中进行治疗和/或预防的药物试剂，并且具体来说涉及螺二环化合物，包含此类化合物的药物组合物，以及它们作为menin/MLL蛋白/蛋白相互作用抑制剂用于治疗如下疾病：例如，癌症、骨髓增生异常综合症(MDS)和糖尿病的用途。

USPTO Abstract

本发明涉及用于在哺乳动物中进行治疗和/或预防的药物试剂，并且具体来说涉及螺二环化合物，包含此类化合物的药物组合物，以及它们作为menin/MLL蛋白/蛋白相互作用抑制剂用于治疗如下疾病：例如，癌症、骨髓增生异常综合症(MDS)和糖尿病的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN109689663B
Jurisdiction
CN
Classification
—
Expires
2023-04-14
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.